Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.

ABSTRACT:

Background

Greater than one-half of patients with melanoma who are treated with antibodies blocking programmed cell death protein 1 receptor (anti-PD-1) experience disease progression. The objective of the current study was to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed while they were receiving anti-PD-1 therapy.

Methods

The authors evaluated 383 consecutively treated patients who received anti-PD-1 for advanced melanoma between 2009 and 2019. Patient and disease characteristics at baseline and at the time of progression, subsequent therapies, objective response rate (ORR), overall survival, and progression-free survival were assessed.

Results

Of 383 patients, 247 experienced disease progression. The median survival a

SUBMITTER: Patrinely JR 

PROVIDER: S-EPMC7695037 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature